World Health Organization VIRAL HEPATITIS Resolution passes

Read the unanimous UN/WHO resolution in full here: http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_R18-en.pdf From IP-Watch article: "The resolution asks states to consider using the flexibilities endorsed in the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) to promote access to specific pharmaceutical products. The director general is also asked to provide necessary technical support to countries, in

PATIENTS, CAREGIVERS: HepCBC NEEDS YOUR INPUT RE: SIMEPREVIR

Simeprevir (trade name GALEXOS™, produced by Janssen, Inc.) was recently approved for use in Canada to treat hepatitis C, but BC PharmaCare doesn't cover it yet. Like similar drugs telaprevir/INCIVEK™ and boceprevir/VICTRELIS™, simeprevir is generally given to genotype 1 patients for several weeks in combination with two other medications (hence the name, "Triple Therapy"). In Triple Therapy with simeprevir, the drug is taken once a day (one pill) along wi

Updates to Canadian sofosbuvir pricing and CADTH queuing schedule

NEW CANADIAN DEVELOPMENTS RE: SOFOSBUVIR'S PRICE AND APPROVAL SCHEDULE GILEAD PRICING OF SOFOSBUVIROn Feb. 24th, 2014 Gilead Sciences announced $55,000 Canadian pricing for its sofosbuvir (SOVALDI™) treatment which is significantly lower than the $84,000 that is being quoted for the USA, and actively opposed by patient advocacy groups there:  "Gilead Sciences Canada Inc. is committed to ensuring the best possible market access for HCV patients who would be